Eric Hu, PhD
Dr. Eric Hu serves as VP of Corporate Development and Strategy at Overland Pharmaceuticals.
Prior to Overland, Dr. Hu was Senior Director of Business Development at Turning Point Therapeutics where he contributed to all aspects of strategic initiatives, deal sourcing, and diligence efforts. Before Turning Point Therapeutics, Dr. Hu spent over ten years at Gilead Sciences with increasing responsibilities from drug discovery to business development diligence. Dr. Hu is a coauthor of several high impact publications including Nature and Nature Medicine. Dr. Hu is also a key contributor and co-inventor of multiple clinical programs in antiviral, oncology, and inflammation including first-in-class long-acting HIV Capsid inhibitor Lenacapavir currently in multiple phase III clinical trials. Dr. Hu brings over 17 years of biopharmaceutical industry experience to Overland.
Dr. Hu received his Ph.D. in organic chemistry from University of California, Los Angeles, and BS from Beijing Normal University with honors.